Mia's Feed
Medical News & Research

New Evidence Supports Use of Weight-Loss Medication for Schizophrenia Patients

New Evidence Supports Use of Weight-Loss Medication for Schizophrenia Patients

Share this article

A groundbreaking study shows that semaglutide, a diabetic weight-loss drug, is safe and effective for reducing obesity in people with schizophrenia without worsening psychiatric symptoms. This promotes better health outcomes for this high-risk group.

2 min read

Recent research conducted by the University of Queensland has demonstrated that certain diabetic weight-loss medications are both effective and safe for individuals with schizophrenia, without exacerbating their psychiatric symptoms. In a 36-week clinical trial, the medication semaglutide—commonly found in drugs like Ozempic and Wegovy—was shown to significantly aid weight loss among patients, a crucial development given the high risk of obesity-related complications in this population.

Patients with schizophrenia often experience weight gain due to antipsychotic medications, such as clozapine, which many find difficult to tolerate long-term. This weight gain can lead to a substantial reduction in life expectancy, with the gap to the general population's lifespan extending to approximately 16 years. The trial revealed that participants taking semaglutide lost nearly 14% of their body weight, compared to those on a placebo, suggesting strong therapeutic potential.

Importantly, the study found that semaglutide did not interfere with mental health, psychotic symptoms, or the levels of antipsychotic drugs. It also improved the ratio of lean to fat mass, indicating more effective fat loss. These findings are particularly notable because they were obtained without pharmaceutical company involvement, adding to their credibility.

Currently, in Australia, semaglutide is not included in the Pharmaceutical Benefits Scheme (PBS) for weight management, underscoring the need for wider access due to the urgent health disparities faced by people with schizophrenia. Experts advocate for policy changes to improve affordability and availability, enabling this vulnerable group to benefit from such effective treatment options.

This pioneering research, published in The Lancet Psychiatry, offers a promising avenue for improving physical health outcomes in individuals with schizophrenia, supporting both weight management and overall well-being.

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

Strengthening Relationships Enhances Resilience for Dementia Caregivers, New Study Shows

Investing in loving relationships can build emotional resilience for dementia caregivers, helping them navigate behavioral changes and maintain meaningful connections over time.

Early Detection of West Nile Virus in Massachusetts Raises Public Health Alerts

Massachusetts reports early detection of West Nile virus in mosquitoes, prompting health advisories and preventive actions for residents to reduce mosquito bites and disease risk.

Rising Use of Nicotine Pouches Among Teens Sparks Public Health Concerns

The increasing popularity of smokeless nicotine pouches among teens raises significant health concerns. Experts warn about early addiction risks and the challenges in regulation and education, emphasizing the need for awareness and prevention.

Enhancing Prevention Strategies for Common Type of Stroke: Insights from Recent Research

New research shows that modifiable risk factors like smoking and high blood pressure are key to preventing the common type of stroke—subarachnoid hemorrhage—which remains a significant health concern worldwide. Proactive public health efforts can further reduce its incidence and related disabilities.